REVIEW

COVID-19 in ophthalmic practice

About authors

1 Pirogov Russian National Research Medical University, Moscow, Russia

2 Department of ophthalmology of Federal Scientific-Clinical Center of Otorhinolarygology of Federal Medico-Biological agency, Moscow, Russia

Correspondence should be addressed: Marina Kh. Movsesian
Ostrovityanova, 1, Moscow, 117437; ur.liam@niramvom

About paper

Author contribution: Takhchidi KhP — study concept and design, text editing; Takhchidi NKh — study design, analysis of the list of literature, text editing; Movsesyan MKh — study design, literature collection and analysis, article authoring.

Received: 2020-09-13 Accepted: 2020-10-03 Published online: 2020-11-29
|
  1. Wang LS, Wang YR, Ye DW, Liu QQ. A review of the Novel Coronavirus (COVID-19) based on current evidence. Int J Antimicrob Agents. 2019; 2020. DOI: 10.1016/j.ijantimicag.2020.105948.
  2. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 283: 727–33.
  3. Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19. Clin Exp Optom. 2020; 103 (4): 418–24. DOI:10.1111/cxo.13088.
  4. Casagrande M, Fitzek A, Püschel K, Aleshcheva G, Schultheiss H-P, Berneking L, et al. Detection of SARS-CoV-2 in Human Retinal Biopsies of Deceased COVID-19 Patients. Ocular Immunology and Inflammation. 2020 Jul 29; 28 (5): 721–5.
  5. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020. Availabe from: https://doi.org/10.1128/JVI.00127-20.
  6. Ahmetshin RF, Rizvanov AA, Bulgar SN, i dr. Koronavirusnaja infekcija i oftal'mologija. Kazanskij medicinskij zhurnal. 2020; 101 (3): 371–80. DOI: 10.17816/KMJ2020-371.
  7. Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 2020; 18 (3): 360–2. DOI: 10.1016/j.jtos.2020.03.010.
  8. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L. Characteristics of ocular findings of patients with coronavirus disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol. 2020; 138 (5): 575–8. DOI: 10.1001/jamaophthalmol.2020.1291.
  9. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020; 28 (3): 391–5. DOI: 10.1080/09273948.2020.1738501.
  10. Tong T, Lai TS. The severe acute respiratory syndrome coronavirus in tears. Br J Ophthalmol. 2005; 89 (3): 392.
  11. Chan WM, Yuen KS, Fan DS, Lam DS, Chan PK, Sung JJ. Tears and conjunctival scrapings for coronavirus in patients with SARS. DOI: 10.1136/bjo.2003.039461. Available from: https://pubmed. ncbi.nlm.nih.gov/15205249/.
  12. Willcox MD, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID-19.ClinExpOptom. 2020; 103 (4): 418–24. DOI: 10.1111/cxo.13088.
  13. Zhang X, Chen X, Chen L, et al. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 2020; 18 (3): 360–2. DOI: 10.1016/j.jtos.2020.03.010.
  14. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm. 2020; 28 (3): 391–5. DOI: 10.1080/09273948.2020.1738501.
  15. Doherty MJ. Ocular manifestations of feline infectious peritonitis. J Am Vet Med Assoc. 1971; 159: 417–24.
  16. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46: 586–90.
  17. Landecho MF, Yuste JR, Gándara E, Sunsundegui P, Quiroga J, Alcaide AB, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? Journal of Internal Medicine. 2020. DOI: 10.1111/joim.13156.
  18. Raony I, Saggioro de Figueiredo C. Retinal outcomes of COVID-19: Possible role of CD147 and cytokine storm in infected patients with diabetes mellitus. 2020; 165: 108280. Aailable from: https://doi.org/10.1016/j.diabres.2020.108280.
  19. Quintana-Castanedo L, Feito-Rodríguez M, Fernández-Alcalde C, et al. Concurrent chilblains and retinal vasculitis in a child with COVID-19 [published online ahead of print, 2020 Jul 2]. J Eur Acad Dermatol Venereol. 2020; 10.1111/jdv.16801. DOI: 10.1111/jdv.16801.
  20. Vavvas DG, Sarraf D, Sadda SR, et al. Concerns about the interpretation of OCT and fundus findings in COVID-19 patients in recent Lancet publication [published online ahead of print, 2020 Jul 9]. Eye (Lond). 2020; 1–2. DOI: 10.1038/s41433-020-1084-9.
  21. Ruamviboonsuk P, Lai TYY, Chang A, et al. Chloroquine and Hydroxychloroquine Retinal Toxicity Consideration in the Treatment of COVID-19. Asia Pac J Ophthalmol (Phila). 2020; 9 (2): 85–87. DOI: 10.1097/APO.0000000000000289.
  22. Marmor MF. COVID-19 and Chloroquine/Hydroxychloroquine: is there Ophthalmological Concern? Am J Ophthalmol. 2020; 213: A3–A4. DOI: 10.1016/j.ajo.2020.03.028.
  23. Yusuf IH, Foot B, Galloway J, et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye (Lond). 2018; 32 (7): 1168–73. DOI: 10.1038/s41433-018-0136-x.
  24. Xu C, Zhu L, Chan T, et al. Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2. J Pharm Sci. 2016; 105 (2): 884–90. DOI: 10.1002/jps.24663.
  25. Moschos MM, Nitoda E, Chatziralli IP, Gatzioufas Z, Koutsandrea C, Kitsos G. Assessment of hydroxychloroquine maculopathy after cessation of treatment: an optical coherence tomography and multifocal electroretinography study. Drug Des Devel Ther. 2015; 9: 2993–9. Published 2015 Jun 11. DOI: 10.2147/DDDT. S81303.
  26. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014; 132 (12): 1453–60. DOI: 10.1001/jamaophthalmol.2014.3459.